Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
- Author:
Filiz AKYÜZ
1
;
Yoon Kyo AN
;
Jakob BEGUN
;
Satimai ANIWAN
;
Huu Hoang BUI
;
Webber CHAN
;
Chang Hwan CHOI
;
Nazeer CHOPDAT
;
Susan J CONNOR
;
Devendra DESAI
;
Emma FLANAGAN
;
Taku KOBAYASHI
;
Allen Yu-Hung LAI
;
Rupert W LEONG
;
Alex Hwong-Ruey LEOW
;
Wai Keung LEUNG
;
Julajak LIMSRIVILAI
;
Virly Nanda MUZELLINA
;
Kiran PEDDI
;
Zhihua RAN
;
Shu Chen WEI
;
Jose SOLLANO
;
Michelle Mui Hian TEO
;
Kaichun WU
;
Byong Duk YE
;
Choon Jin OOI
Author Information
- Publication Type:Review
- From:Intestinal Research 2025;23(1):37-55
- CountryRepublic of Korea
- Language:English
- Abstract: The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.
